BIO-TECHNE CORP shareholders Q3 2023

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Echo Street Capital Management LLC 4,090$278,4060.00%
CAPSTONE INVESTMENT ADVISORS, LLC 8,535$580,9770.00%
West Tower Group, LLC 94$6,3990.00%
PICTON MAHONEY ASSET MANAGEMENT 1,645$1120.00%
Castleview Partners, LLC 55$3,7440.00%
Janney Montgomery Scott LLC 10,329$7030.00%
Tradition Wealth Management, LLC 424$290.00%
BANK OF AMERICA CORP /DE/ 436,833$29,735,2400.00%
BESSEMER GROUP INC 19,653$1,3390.00%
BANK OF NOVA SCOTIA 14,613$994,7070.00%
Rathbones Group PLC 5,541$377,1750.00%
NATIONAL BANK OF CANADA /FI/ 33,630$2,258,2540.00%
SIGNATUREFD, LLC 1,851$125,9980.00%
DekaBank Deutsche Girozentrale 20,880$1,4150.00%
CAPITAL FUND MANAGEMENT S.A. 10,794$734,7470.00%
TRUIST FINANCIAL CORP 20,077$1,366,6160.00%
Alberta Investment Management Corp 3,100$211,0170.00%
CENTRAL TRUST Co 988$67,2540.00%
CREDIT AGRICOLE S A 1,481$100,8120.00%
HighTower Advisors, LLC 18,866$1,290,0000.00%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.